/

Simnorreltir Tablenq/Rironatir Tablenq (co-packaged)
Xiannsoreuei Pian/Lirsonauei Pian Zshebaoxhsang

:(S)-N-((S)- - -(S)- - - -))- -((S)- ,
- - -(, , -))- , - - - [.]

C H F N O S

[(αS)-α-[(S, S)- - -[(S)- -[-[(- - -)
]- -]- -]- -]]

C H N O S

YO sD s COVID- ŷ ű ∀ q ≠
Ó Ó

Encorafenib

Foqramarinib

Nerarinib

Veneroclav

Δ

mbo

CYP A

CYP C

R-

--
S-

R-

p

/

Simnorreltir Tablerq/Rironatir Tablerq (co-packaged)
Xiannsoreuei Pian/Lirsonauei Pian Zshebaoxhsang

:(S)-N-((S)- - - -((S)- - - -))- -((S)- ,
- - -(, , -))- , - - - [.]

:
C H F N O S
.

[(αS)-α-[(S, S)- - - -[(S)- -[-[(- - -)
]- -]- -]- -]]

C H N O S
.

)Q
Y FÓN Gd sD s COVID- ý ů ∀ q ≠
Ï
Ò Ô

α

Nerarinib

Neraríníb

Veneroclav

Veneroclav

/

N

ESRD

eGFR mL/min ESRD

HIV-1 HIV- HIV- HIV

mmol mg

mg/kg/

SIM -

B B -

CYP A P-gp

CYP A P-gp

/ . g/ . g CYP A

CYP A u v u v p

CYP3A4

mg / . g/ . g Cmav ˘

AUC -τ AUC -∞ % % %| % ˘ % %| % % %| % p

CYP A u v p

AUCtau h³ng/mL	. . %	. %
AUC -∞ h³ng/mL	. . %	. %
Cmav ng/mL	. . %	. . %
r / h	. - .	. - .
Tmav h	. . - .	. . - .

3 -

mg	mg	AUC	Cmin
q h	q h	↑ %	↑
CYP A p		mg	
mg p		p	
q h	q h	↑ %	↑
		↑	↑ ª
CYP A p			mg
mg p		p	
q h		↑	
CYP A p			p
mg p		p	
q h	q h	↑ .	↑
CYP A p		p	
p	mg	mg	
p mg		p	p
q h	q h	↑ %	ND
		↑ %	ND
q h	q h	↔	↑
		↔	↔
CYP A p			
p mg		p	mg
mg		p	
q h	q h	↑ - %	ND
	q h	↑ %	ND
		↔	↔
CYP A p			
p mg		p	
q h	q h	↑	↑
q h	q h	↔	↔
		↑	ND
		↔	↔
CYP A p		p	mg
mg			mg
˘ p			
mg	mg	mg	p
-			
/ p			
p			
q h	q h	↑	↑
		↓ %	ND
CYP A p			p
mg		p	p

4 -

mg mg

q h q h h ↓ % ↔

↔ ↔

Encorafenib

Foqramarinib

Nerarinib

Veneroclav

Δ

CYP A CYP C R- ↔ S-

R-

p

/ mg| mg / mg| mg
Cmav ĻĻQTcF %CI mq p mgBID
Cmav ĻĻQTcF %CI mq p
/ p CYP A
p
. g Cmav AUC - h AUC -∞ ng /mL ng h/mL
ng h/mL T/ . h Tmav . h / . g/ . g Cmav
AUC - h -AUC -∞ ng /mL ng h/mL ng h/mL T/ . h Tmav . h
p / . g/ . g Cmav
AUC - h AUC -∞ . g . . . p

mavma Ɋ ⓖ mav / . g/ . g| . g/ . g
. g| . g Cmav AUC . g| . g
p / . g/ . g| . g/ . g
Cmav

	/ 0.750g/0.1g N=24	/ 0.750g/0.1g N=12	/ 0.750g/0.1g N=12
AUC -∞ (h³ng/mL)	(. %)	(. %)	(. %)

	(. %)	(. %)	(. %)
	(. %)	(. %)	(. %)
	. - .	. - .	. - .
	. .	. .	ő

ɹ ʒ

ɹ ʃ

ɹ ʃ

ɹ ʃ